Yuvezzi launches with direct-to-patient cost of $198 for 90 days

Tenpoint Therapeutics has launched Yuvezzi (carbachol and brimonidine tartrate), which treats presbyopia, or blurry vision due to aging. Approved in January 2026, Yuvezzi is a once-daily eye drop to treat presbyopia in adults. It contains carbachol, a cholinergic agonist that mimics the neurotransmitter acetylcholine, and brimonidine tartrate, which is available as a generic to lower pressure inside the eye.

Presbyopia is the loss of the ability to focus on near objects as a result of the natural aging process. It occurs mostly after the age of 40 when the crystalline lens of the eye gradually stiffens and loses flexibility. Almost 2 billion people globally and more than 128 million people in the United States live with presbyopia.

“As we age, blurry close-up vision can turn simple, everyday moments like reading a text, checking a receipt or reviewing a menu into a frustrating challenge.” Carol Kearney, chief operating officer of Tenpoint Therapeutics, said in a news release.

Yuvezzi is available at retail pharmacies or directly to patients through PHIL, an all-in-one digital hub and direct-to-patient platform. It is available for $79 for 30 single-use vials or $198 for 90 single-use vials. GoodRx also provides discounts for Yuvezzi.

Last year, the FDA approved a single-agent therapy, VIZZ (acedidine), a once-daily eye drop for adults with presbyopia. The manufacturer, LENZ Therapeutics, sells VIZZ directly to patients or through Amazon Pharmacy for $79 a month or $198 for three months.

The FDA approval of Yuvezzi is based on positive data from two phase 3 studies. The phase 3 BRIO I study demonstrated the benefit of the combination therapy over the individual components, which is a requirement for FDA approval of a fixed-dose combination.

In the second phase 3 study, BRIO II, which was vehicle-controlled, Yuvezzi achieved all primary near vision improvement endpoints with a statistically significant three-line or greater improvement in binocular uncorrected near visual acuity (BUNVA) over eight hours, without the loss of one line or more in binocular uncorrected distance visual acuity (BUDVA). BUNVA and BUDVA are two measures to assess vision using both eyes without glasses.

Yuvezzi was well tolerated, with no treatment-related serious adverse events observed in the more than 72,000 treatment days monitored in BRIO II. The most common adverse events were headache, impaired vision, and temporary eye pain or eye irritation.

In both trials, the reports of adverse events of ocular hyperemia (eye redness) were low. In BRIO II, the rate of reported eye redness was lower in patients receiving Yuvezzi than in those receiving carbachol alone.